Open AccessRelugolix Combination Therapy for Uterine Leiomyoma–Associated Pain in the LIBERTY Randomized Trials
Author(s) -
Elizabeth A. Stewart,
Andrea S. Lukes,
Roberta Venturella,
Joaquim J. Ferreira,
Yulan Li,
Elke Hunsche,
Rachel B. Wagman,
Ayman AlHendy
Publication year - 2022
Publication title -
obstetrics and gynecology (new york. 1953. online)/obstetrics and gynecology
Language(s) - English
Resource type - Journals
eISSN - 1873-233X
pISSN - 0029-7844
DOI - 10.1097/aog.0000000000004787
Subject(s) - medicine , placebo , leiomyoma , randomized controlled trial , menstrual cycle , clinical endpoint , visual analogue scale , gynecology , obstetrics , surgery , alternative medicine , pathology , hormone
To assess the effect of once-daily relugolix combination therapy (relugolix-CT: relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) compared with placebo on moderate-to-severe pain in women with uterine leiomyomas and heavy menstrual bleeding.